Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Boomray Pharmaceuticals

Tracked across 1 events · 6 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026

Sentiment
70
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 70
Business
Boomray Pharmaceuticals Co., Ltd. announced on September 22, 2026 that it has entered into an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. Under the terms, BoomRay…
Impact: Licensor of the preclinical RLT asset; gains up to USD 900 million in upfront and milestone payments plus royalties, validating its discovery platform and improving its funding position.
Sep 22, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Boomray Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.